« Back
Home /
Alvespimycin

Alvespimycin

Item no.	HY-10389-25mg
Manufacturer	MedChem Express
CASRN	467214-20-6
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 1 mg 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Oncology Food Safety Allergenes Neuroscience Neuroinflammation Protein Aggregation, Clearance & Misfolding Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Breast Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.59
Citations	[1]Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49(15):4606-15.\|[2]Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116(1):45-53.\|[3]Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77. Acs Biomater Sci Eng. 2021 Oct 12.\|Cell Death Dis. 2022 Jan 21;13(1):73.\|Exp Ther Med. February 10, 2022.\|Friedrich-Alexander University Erlangen-Nuremberg. 2016 Sep 14.\|NPJ Precis Oncol. 2023 May 18;7(1):44.\|Pharmacol Res. 2020 Jan;151:104512.\|Sci Rep. 2021 May 26;11(1):11057.\|Theranostics. 2020 Jul 9;10(18):8415-8429.\|Authorea. April 10, 2021.\|Biochim Biophys Acta Mol Cell Res. 2024 Mar 5:119703.\|bioRxiv. 2021 Jan 27.\|Br J Pharmacol. 2021 Nov;178(22):4485-4500.\|Front Pharmacol. 14 January 2022.\|Nat Commun. 2021 Jul 22;12(1):4457.
Smiles	C/C1=C\C=C/[C@@H]([C@H](/C(C)=C/[C@@H]([C@H]([C@H](C[C@@H](CC(C(C(NC1=O)=CC2=O)=O)=C2NCCN(C)C)C)OC)O[H])C)OC(N)=O)OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	17-DMAG,KOS-1022,NSC 707545
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	HSP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	616.75
Product Description	Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 ± 29 nM.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Isoform	HSP90
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10389-25mg-safety-datasheet.pdf